Evaluating Opicapone as Add-on Treatment to Levodopa/DDCI in Patients with Parkinson’s Disease

References

• S3 guideline idiopathic Parkinson’s disease. AWMF-Register-Nummer: 030–010; 2016. https://www.awmf.org/uploads/tx_szleitlinien/030-010k_S3_Parkinson_Syndrome_Idiopathisch_2016-06-abgelaufen.pdf. Accessed July 19, 2022.
   Google Scholar
• Oertel WH, Berardelli A, Bloem BR, et al. Early (uncomplicated) Parkinson’s disease. Eur Handb Neurol Manag. 2011;1:217–236.
   Google Scholar
• Tambasco N, Romoli R, Calabresi P. Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol. 2018;16(8):1239–1252. doi:10.2174/1570159X15666170510143821
   PubMed Web of Science ®Google Scholar
• SmPC Tolcapone. Available from: https://www.ema.europa.eu/en/documents/product-information/tasmar-epar-product-information_en.pdf. Accessed April 25, 2022.
   Google Scholar
• SmPC Entacapone. Available from: https://www.ema.europa.eu/en/documents/product-information/entacapone-orion-epar-product-information_en.pdf. Accessed April 25, 2022.
   Google Scholar
• Song Z, Zhang J, Xue T, et al. Different catechol-O-methyl transferase inhibitors in Parkinson’s disease: a Bayesian network meta-analysis. Front Neurol. 2021;12. doi:10.3389/fneur.2021.707723
   Web of Science ®Google Scholar
• Rocha F, Almeida L, Falcão A, et al. Opicapone: a short lived and very long-acting novel catechol- O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76(5):763–775. doi:10.1111/bcp.12081
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154–165. doi:10.1016/S1474-4422(15)00336-1
   PubMed Web of Science ®Google Scholar
• Bonifacio MJ, Sousa F, Loureiro A, et al. Evaluation of potential mechanisms of cellular toxicity by nitrocatechol COMT inhibitors: opicapone, entacapone and tolcapone Presented at: XX World Congress on Parkinson’s Disease and Related Disorders; 2013; Geneva, Switzerland.
   Google Scholar
• Kiss LE, Ferreira HS, Torrao L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2010;53(8):3396–3411. doi:10.1021/jm1001524
   PubMed Web of Science ®Google Scholar
• Palma PN, Bonifacio MJ, Loureiro AI, et al. Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstrate relative free energy calculations. J Comput Chem. 2012;33(9):970–986. doi:10.1002/jcc.22926
   PubMed Web of Science ®Google Scholar
• Almeida L, Rocha JF, Falcao A, et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet. 2013;52(2):139–151. doi:10.1007/s40262-012-0024-7
   PubMed Web of Science ®Google Scholar
• Rocha JF, Almeida L, Falcao A, et al. Opicapone: a short lived and very long-acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76(5):763–775.
   PubMed Web of Science ®Google Scholar
• ClinicalTrails.gov, NCT02169440. Effect of BIA 9–1067 on the pharmacokinetics and pharmacodynamics of Warfarin. Available from: https://clinicaltrials.gov/ct2/show/NCT02169440. Accessed July 19, 2022.
   Google Scholar
• Rocha JF, Falcao A, Santos A, et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol. 2014;70(9):1059–1071. doi:10.1007/s00228-014-1701-2
   PubMed Web of Science ®Google Scholar
• Bonifacio MJ, Torrao L, Loureiro AI, Wright LC, Soares-da-Silva P. Opicapone: characterization of a novel peripheral long acting catechol-O-methyltransferase inhibitor. Parkinsonism Relat Disord. 2012;18(suppl2):S125.
   Google Scholar
• Falcao A, Rocha JF, Santos A, et al. Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects. Clin Pharmacol Drug Dev. 2016;5(2):150–161. doi:10.1002/cpdd.213
   PubMed Web of Science ®Google Scholar
• Rocha JF, Santos A, Falcao A, et al. Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol. 2014;70(3):279–286. doi:10.1007/s00228-013-1602-9
   PubMed Web of Science ®Google Scholar
• SmPC Opicapon. https://www.ema.europa.eu/en/documents/product-information/ongentys-epar-product-information_en.pdf. Accessed April 25, 2022.
   Google Scholar
• Ferreira J, Lees A, Rocha JF, et al. Opicapone ́s efficacy in Parkinson ́s disease patients with motor fluctuations: a Phase III, randomised, double- blind, placebo and active-controlled study - BIPARK I study. Poster presented at theXXII World Congress of Neurology; October 31–November 5; 2015; Santiago, Chile.
   Google Scholar
• Lees A, Ferreira JJ, Costa R, et al. Efficacy and safety of opicapone, a new COMT inhibitor, for the treatment of motor fluctuations in Parkinson’s disease patients: BIPARK-II study [abstract no. 1038]. J Neurol Sci. 2013;333(suppl 1):e116. doi:10.1016/j.jns.2013.07.391
   Google Scholar
• Ferreira JJ, Lees A, Santos A, et al. Pooled efficacy analysis of opicapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and motor fluctuations. Poster presented at the 1st Congress of the European Academy of Neurology; June 20-23; 2015; Berlin.
   Google Scholar
• Ferreira JJ, Lees A, Rocha JF, et al. Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: a pooled-analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol. 2019;3:1331–1468.
   Google Scholar
• Ferreira JJ, Lees A, Tolosa E, et al. Switching double-blind opicapone, entacapone or placebo to open-label opicapone: efficacy results of the 1-year extension of study BIPARK I. Mov Disord. 2016;31(suppl 2):S633.
   Google Scholar
• Costa R, Oliveira C, Pinto R, et al. One-year open-label efficacy and safety of opicapone in Parkinson’s disease BIPARK-II study. Mov Disord. 2014;29(suppl1):S233.
   Google Scholar
• Oliveira C, Lees A, Ferreira J, et al. Opicapone and non-motor symptoms in Parkinson ́s disease: results from double-blind, randomized, placebo-controlled study and open-label extension. Mov Disord. 2015;30(Suppl1):p173.
   Google Scholar
• Lees A, Rascol O, Ferreira JJ, et al. Effect of opicapone and entacapone on daily pattern of motor fluctuations in Parkinson’s disease patients. Mov Disord. 2020;35(suppl 1):461; abst 1027.
   Google Scholar
• Videnovic A, Poewe W, Lees A, et al. Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson’s disease patients with motor fluctuations. Mov Disord. 2020;35(suppl1):466;abst 1071.
   Google Scholar
• Katzenschlager R, Ferreira JJ, Chaudhuri KR, et al. What to do when the honeymoon wears OFF. CNS. 2022;7(2):1–32.
   Google Scholar
• Lopes N, Ferreira J, Lees A, et al. Efficacy of opicapone in Parkinson’s disease patients with motor fluctuations at different stages of symptom progression. Eur J Neul. 2016;23(suppl 1):601–879.
   Google Scholar
• Rocha F, Ebersbach G, Lees A, et al. The added benefit of opicapone when used early in parkinson’s disease patients with levodopa-induced motor fluctuations: a post-hoc analysis of BIPARK-I and -II. Front Neurol. 2021;12(Article):754016. doi:10.3389/fneur.2021.754016
   Web of Science ®Google Scholar
• LeWitt P, Stocchi F, Ferreira JJ, et al. Efficacy of opicapone at different levodopa regimens up to a threshold of 600 mg/day levodopa in Parkinson’s Disease patients with motor fluctuations. Neurology. 2020;88(suppl 25):187;abst490.
   Google Scholar
• Ebersbach G, Rascol O, Ferreira JJ, et al. Efficacy and safety of opicapone in Parkinson’s disease patients according to duration of motor fluctuations: post-hoc analysis of BIPARK-I and II. Mov Disord. 2020;35(suppl 1):444;abst 993.
   Google Scholar
• Ferreira F, Lees A, Ebersbach G, et al. Efficacy of opicapone compared to entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations: a post-hoc conservative analysis. Mov Disord. 2020;35(suppl 1):447;abst 998.
   Google Scholar
• Antonini A, Ebersbach G, Rascol O, et al. Efficacy of opicapone in different treatment regimens in Parkinson’s disease patients with motor fluctuations. Park Relat Disord. 2020;79:e64–e65. doi:10.1016/j.parkreldis.2020.06.239
   Web of Science ®Google Scholar
• Lees A, Ferreira J, Lopes N, et al. Efficacy and safety of opicapone in patients over 70 years with Parkinson’s disease and motor fluctuations. Mov Disord. 2015;30(suppl 1):99.
   Google Scholar
• Reichmann H, Rocha R, Lees A, et al. Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener. 2020;9:9. doi:10.1186/s40035-020-00187-1
   PubMed Web of Science ®Google Scholar
• Oehlwein C, Mittmann K, Witt K, et al. Opicapone improves motor and non-motor wearing OFF symptoms in Parkinson’s disease: an observational real-world study. Poster presented at MDS; 2019; Agora 3 West.
   Google Scholar
• Braak H, Rüb U, Gai WP, et al. Diopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110(5):517–536. doi:10.1007/s00702-002-0808-2
   PubMed Web of Science ®Google Scholar
• Braak H, Tredici KD, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211. doi:10.1016/S0197-4580(02)00065-9
   PubMed Web of Science ®Google Scholar
• Svensson E, Horváth-Puhó E, Thomsen RW, et al. Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol. 2015;78(4):522–529; PMID: 26031848. doi: 10.1002/ana.24448
   PubMed Web of Science ®Google Scholar
• Rekdal V, Bess EN, Bisanz JE, et al. Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. Science. 2019;364(6445):eaau6323. doi:10.1126/science.aau6323
   Web of Science ®Google Scholar
• Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66–72. PMID: 27591074. doi:10.1016/j.parkreldis.2016.08.019
   PubMed Web of Science ®Google Scholar
• Laval L, Martin R, Natividad JN, et al. Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut Microbes. 2015;6(1):1–9; PMID: 25517879; PMCID: PMC4615674. doi: 10.4161/19490976.2014.990784
   PubMed Web of Science ®Google Scholar
• Martín R, Miquel S, Chain F, et al. Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol. 2015;15(1):67. PMID: 25888448; PMCID: PMC4391109. doi:10.1186/s12866-015-0400-1
   Web of Science ®Google Scholar
• Keshavarzian A, Green SJ, Engen PA, et al. Colonic bacterial composition in Parkinson’s disease. Mov Disord. 2015;30(10):1351–1360; PMID: 26179554. doi: 10.1002/mds.26307
   PubMed Web of Science ®Google Scholar
• Cantu-Jungles TM, Rasmussen HE, Hamaker BR. Potential of prebiotic butyrogenic fibers in Parkinson’s disease. Front Neurol. 2019;10:663. PMID: 31281287; PMCID: PMC6595503. doi:10.3389/fneur.2019.00663
   Web of Science ®Google Scholar
• Grün D, Zimmer VC, Kauffmann J, et al. Impact of oral COMT-inhibitors on gut microbiota and short chain fatty acids in Parkinson’s disease. Parkinsonism Relat Disord. 2020;70:20–22. PMID: 31790924. doi:10.1016/j.parkreldis.2019.11.020
   Web of Science ®Google Scholar
• Müller T New developments in Parkinson’s disease therapy with COMT inhibitors. Symposium presented at the 89th Congress of the German Society of Neurology; September 22; 2016; Mannheim, Germany.
   Google Scholar
• Rascol O, Poewe W, Ferreira JJ, et al. Efficacy of opicapone in patients with Parkinson’s disease with levodopa dose reduction: a pooled post-hoc analysis of BIPARK-I and II. Eur J Neurol. 2020;27(suppl1):1105;abst 3148.
   Google Scholar
• Rocha JF, Falcão A, Santos A, et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol. 2014;70(9):1059–1071. doi:10.1007/s00228-014-1701-2
   PubMed Web of Science ®Google Scholar
• Najib J. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson’s disease. Clin Ther. 2001;23(6):802–832. doi:10.1016/S0149-2918(01)80071-0
   PubMed Web of Science ®Google Scholar
• Loewen G, Vijan A, Olson K, et al. Effects of once-daily opicapone 50 mg on the pharmacokinetics of levodopa administered as carbidopa/levodopa extended-release capsules: an open-Label Phase 1 study. Mov Disorders. 2021;36(suppl. 1):1.
   Google Scholar
• Ferreira J, Poewe W, Rascol O, et al. Study-design to assess the effect of opicapone on levodopa PK at different levodopa-optimized treatment regimens. Eur J NeuroL. 2021;28(suppl.1):558–752. doi:10.1111/ene.14557
   Web of Science ®Google Scholar
• Ferreira J, Poewe W, Rascol O, et al. The ADOPTION (eArly levoDopa with Opicapone in Parkinson’s paTients wIth motOr fluctuatioNs) study in Parkinson’s disease: design and rationale of a randomized prospective, open-label exploratory trial. Mov Disorders. 2021;36(suppl.1):36.
   Google Scholar
• Clinicaltrails.gov, NCT04990284. eArly levoDopa with opicapone in Parkinson’s paTients wIth motOr fluctuatioNs. (ADOPTION). Available from: https://clinicaltrials.gov/ct2/show/NCT04990284. Accessed July 19, 2022.
   Google Scholar
• Ferreira J, Poewe W, Rascol O, et al. The EPSILON (Early Parkinson’s with L-dopa/DDCi and OpicapoNe) study in early Parkinson’s disease: design and rationale of a phase III, double-blind, randomized, placebo-controlled study. Mov Disorders. 2021;36(suppl.1):2.
   Google Scholar
• Clinicaltrails.gov, NCT04978597. Early Parkinson wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study) (EPSILON). Available from: https://clinicaltrials.gov/ct2/show/NCT04978597. Accessed July 19, 2022.
   Google Scholar